Catheter Precision, Inc. Common Stock VTAK 深 沪
等待开盘 11-03 09:30:00 美东时间
2.45
+0.050
+2.08%
华盛通- 最 高2.56
- 今 开2.43
- 成交量 3.20万股
- 最 低 2.43
- 昨 收 2.40
- 总市值 300.81万
- 52周最高 15.6807
- 市盈率 静 --
- 换手率 2.61%
- 52周最低 2.20
- 委 比 -20.63%
- 总股本 122.78万
- 历史最高 5225000.00
- 量 比 1.38
- 振 幅 5.42%
- 历史最低 2.43
- 每 手 1
- 风险率 2.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
Catheter Precision, Inc., a US-based medical device company, has signed a strategic distribution agreement with FuMedica AG, a leading Swiss distributor, to introduce its LockeT suture retention device to hospitals and clinics across Switzerland. LockeT is a Class 1 FDA-registered and CE-approved device designed to simplify vascular access site closure following cardiac procedures. FuMedica AG, renowned for its expertise in distributing advanced ...
10-16 12:00
Catheter Precision Increases Authorized Shares to 500 Million
An announcement from Catheter Precision ( ($VTAK) ) is now available. On Octobe...
10-16 04:54
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 32.1% to...
10-09 05:06
Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
Catheter Precision, Inc. announced the allowance for two new patents from the USPTO. The first, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," enhances the VIVO technology portfolio for Kardionav. The second, "Neurostimulation Devices and Methods," focuses on improving cardiac ventricular function, particularly for heart failure patients, under Cardionomix. CEO David Jenkins highlighted the importance of these patents in creat...
09-30 12:00
Catheter Precision Announces Tender Win and First Purchase Order in Croatia
Catheter Precision, Inc. announced it received its first purchase order from Dubrava University Hospital in Croatia following a competitive bid. The hospital's evaluation highlighted the effectiveness of the company's VIVO 3D imaging system, which aids in identifying the origin of ventricular arrhythmias. This marks a significant milestone for Catheter Precision, reflecting growing acceptance of its technology in Europe and underscoring its commi...
09-10 12:00
Catheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders
<p>Catheter Precision, Inc. announced that September 10, 2025, is the Record Date for its October 10, 2025, Special Meeting of stockholders. The meeting will seek stockholder approval to amend the Certificate of Incorporation to increase authorized common shares and appoint WithumSmith+Brown, PC as the independent auditor for fiscal 2026. A preliminary proxy statement is anticipated to be filed with the SEC on September 4, 2025.</p>
09-04 20:15
Catheter Precision Announces Introduction of the LockeT Product Line into Italy
Catheter Precision, Inc. announced the introduction of LockeT in Italy, following successful clinical evaluations in France and Germany. The first procedures in Italy were performed at ASST Valle Olona Hospital under the guidance of Dr. Manuela Bianchi. After a successful evaluation, the company received its first commercial purchase order from long-time partner Precise Srl. David Jenkins, CEO of Catheter Precision, expressed enthusiasm about Loc...
09-02 12:00
Catheter Precision Announces First Procedures in France as LockeT Expansion Continues
<p><p>FORT MILL, S.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US-based medical device company and leader in innovative cardiac electrophysiology solutions, announced the first LockeT procedures in France. This milestone demonstrates significant progress in the adoption and commercialization of its technologies across Europe. The procedures were successfully completed at CHU Rennes, led by Professor Ra...
08-28 12:00
Catheter Precision Receives Notification of New Patent Issuance for VIVO Product Line
Catheter Precision, Inc. announced receipt of a new patent for its VIVO system, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model," enhancing its IP portfolio and advancing non-invasive arrhythmia detection.
08-25 12:00
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
